Veru (VERU)
(Real Time Quote from BATS)
$1.26 USD
+0.05 (4.13%)
Updated Apr 26, 2024 03:56 PM ET
2-Buy of 5 2
F Value F Growth A Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
VERU 1.26 +0.05(4.13%)
Will VERU be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for VERU based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for VERU
What Makes Veru (VERU) a New Buy Stock
After Plunging -15.61% in 4 Weeks, Here's Why the Trend Might Reverse for Veru Inc. (VERU)
VERU: What are Zacks experts saying now?
Zacks Private Portfolio Services
Bio-Rad Laboratories (BIO) to Post Q4 Earnings: What Awaits?
Charles River (CRL) to Report Q4 Earnings: What's in Store?
Veru Inc. (VERU) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
Other News for VERU
Veru to Present at the American Association of Clinical Endocrinology (AACE) 2024 Annual Meeting on May 9-11
LI, VERU and MRIN among pre-market losers
Veru, EyePoint Pharmaceuticals, Sintx Technologies among healthcare movers
Veru, EyePoint Pharmaceuticals, SINTX Technologies among healthcare movers
Truist healthcare analyst to hold an analyst/industry conference call